Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
Fecha de publicación2010
Safont, M. J.
MetadatosMostrar el registro completo del ítem
BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study. METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of 30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks. RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and 18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome (19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of previous reports in elderly patients. CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be unsuitable for receiving polychemotherapy.
Es parte deBritish Journal of Cancer, 2010, vol. 102, p. 1468-1473
Proyectos de investigación europeos
El ítem tiene asociados los siguientes ficheros de licencia:
Showing items related by title, author, creator and subject.
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab treated patients with metastatic colorectal cancer Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Losa, F.; Bosch, Carlos; Escudero, P.; Casado, Enrique; Jorge, Monica; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Custodio, Ana B.; Maurel, Joan (Public Library of Science, 2015)Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA ...
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Serra, O.; Vera, R.; Casado, Enrique; Jorge, Monica; Escudero, P.; Bosch, Carlos; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Martínez-Marín, V.; Maurel, Joan (Cancer Research UK, 2014)Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the ...
Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS Wild-Type metastatic colorectal cancer patients Alonso, Vicente; Escudero, Pilar; Fernández-Martos, Carlos; Salud Salvia, Maria Antonieta; Méndez, Miguel; Gallego, Javier; Rodriguez, Jose-R.; Martín-Richard, Marta; Fernández-Plana, Julen; Manzano, Hermini; Méndez, José-Carlos; Zanui, Monserrat; Falcó, Esther; Gil-Raga, Mireia; Rojo, Federico; Cuatrecasas, Miriam; Feliu, Jaime; García-Albéniz, Xabier; Maurel, Joan (Elsevier, 2018)INTRODUCTION: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with ...